Furthermore, the differences in the anti-tumor potential of NKG2A+ and NKG2A− Vδ2 T provide functional indications of their potential uses and indicate the optimal choice according to the immunosuppressive HLA-E-mediated TME. This evidence concerns the gene HLA-E and neoplasm.